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In Alzheimer’s disease (AD), the impairment of declar-
ative memory coincides with the accumulation of
extracellular amyloid-bprotein (Ab) and intraneuronal
tau aggregates. Dementia severity correlates with
decreased synapse density in hippocampus and
cortex. Although numerous studies show that soluble
Ab oligomers inhibit hippocampal long-term potenti-
ation, their role in long-term synaptic depression
(LTD) remains unclear. Here, we report that soluble
Ab oligomers from several sources (synthetic, cell
culture, human brain extracts) facilitated electrically
evoked LTD in the CA1 region. Ab-enhanced LTD
was mediated by mGluR or NMDAR activity. Both
forms of LTD were prevented by an extracellular
glutamate scavenger system. Ab-facilitated LTD
was mimicked by the glutamate reuptake inhibitor
TBOA, including a shared dependence on extracel-
lular calcium levels and activation of PP2B and
GSK-3 signaling. In accord, synaptic glutamate
uptake was significantly decreased by soluble Ab.
We conclude that soluble Ab oligomers perturb
synaptic plasticity by altering glutamate recycling at
the synapse and promoting synapse depression.
INTRODUCTION
Alzheimer’s disease (AD), the most common neurodegenerative
disorder, is characterized by progressive memory and cognitive
impairment and cerebral accumulation of extracellular amyloid
plaques and intraneuronal neurofibrillary tangles. Although the
specific molecular initiators of AD remain unknown in most
patients, extensive research suggests that the amyloid b protein
(Ab) plays an early and essential pathogenic role. Of note,
dementia severity in AD correlates more strongly with cortical
levels of soluble Ab species than with insoluble amyloid plaque
burden (Lue et al., 1999; McLean et al., 1999). Experimentally,
soluble Ab oligomers have been specifically shown to block
hippocampal long-term potentiation (LTP), an electrophysiolog-
ical correlate of learning and memory (e.g., Lambert et al., 1998;
Walsh et al., 2002; Wang et al., 2002; Townsend et al., 2006;788 Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc.Shankar et al., 2008). In accord, impairment of synaptic plasticity
can be detected in vivo before the formation of insoluble Ab
deposits in APP transgenic mouse models (e.g., Hsia et al.,
1999; Mucke et al., 2000). Synthetic Ab aggregates have been
reported to inhibit N-methyl-D-aspartate receptor (NMDAR)-
dependent LTP, but not NMDAR-independent LTP (Chen et al.,
2002; Wang et al., 2004a; but see Raymond et al., 2003). This
finding is consistent with evidence that Ab can affect surface
expression of NMDARs (Snyder et al., 2005; Dewachter et al.,
2009) and may increase (Molna´r et al., 2004; Wu et al., 1995)
or decrease (Chen et al., 2002; Raymond et al., 2003) NMDAR
conductance.
A principal neuropathological finding in AD subjects is cortical
atrophy associated with degeneration of neurites, decreased
dendritic spine density, and frank neuronal loss (Terry et al.,
1991; Knobloch and Mansuy, 2008). Anatomical studies in
normal rodents suggest that the induction of LTP is associated
with spine formation and increased spine volume, whereas the
induction of long-term synaptic depression (LTD) results in
decreased spine volume and spine elimination (Matsuzaki et al.,
2004; Na¨gerl et al., 2004; Zhou et al., 2004; Bastrikova et al.,
2008). Similar to LTP, the induction of LTD in the CA1 region of
hippocampus requires activation of NMDAR and/or metabo-
tropic glutamate receptors (mGluR), depending on the stimula-
tion protocol and recording conditions (Kemp and Bashir,
2001; Anwyl, 2006; Citri and Malenka, 2008). Mechanistically,
synapse potentiation versus depression may ultimately depend
on alterations in cytosolic Ca2+ concentration and the differential
activation of certain kinases and phosphatases, including p38
mitogen-activated protein kinase (MAPK) and calcineurin
(protein phosphatase 2B [PP2B]) (reviewed in Kemp and Bashir,
2001; Citri and Malenka, 2008).
Although numerous reports describe the effects of soluble Ab
species on LTP, only a few studies have examined LTD induc-
tion, and they have yielded inconsistent results. For example,
synthetic Ab peptides were reported to facilitate LTD induction
in an NMDAR-dependent manner in vivo (Kim et al., 2001),
whereas other studies found no effect on LTD in slices (Raymond
et al., 2003; Wang et al., 2002, 2004a). We recently extracted
buffer-soluble Ab directly from the brains of typical AD patients
and showed that this extract, which contains soluble Ab dimers
and trimers, facilitated LTD induction in the CA1 region of mouse
hippocampus by an mGluR-dependent mechanism (Shankar
et al., 2008). Given that both NMDAR and mGluR activation
have been implicated in the effects of Ab on LTD, we asked
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Soluble Ab Enhances Long-Term Depressionwhether glutamate clearance mechanisms are perturbed by Ab.
In addition to affecting synaptic plasticity, excitotoxic effects of
glutamate are believed to contribute to progressive neuronal
loss in AD (Pomara et al., 1992; Harkany et al., 2000). Further-
more, gene expression and protein levels of excitatory amino
acid transporters (EAAT1 and EAAT2) are altered in the hippo-
campus and frontal cortex of AD subjects (Jacob et al., 2007).
Here, we provide evidence that small, soluble Ab assemblies
from several sources enhance synaptic depression through
a mechanism involving altered glutamate uptake at hippocampal
synapses. Our results have both mechanistic and therapeutic
implications for the initiation of hippocampal synaptic failure in
AD and in more subtle forms of age-related Ab accumulation.
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Figure 1. Soluble Ab Facilitates Long-Term
Depression in the CA1 Region of Hippo-
campal Slices
(A) Western blot of the three sources of soluble Ab
used for LTD experiments in this study. All three
contain an SDS-stable band at 8 kDa, and this
has been confirmed previously as an Ab dimer
by mass spectrometry (Shankar et al., 2008).
7PA2 CM also contains a higher, apparent trimer
species. CHO- CM is devoid of these human Ab
species, as expected, and serves as a negative
control throughout these studies. All samples
were immunoprecipitated with polyclonal Ab anti-
body AW8 and blotted with combined Ab mono-
clonal antibodies 2G3 (Ab40) and 21F12 (Ab42).
SEC: fractions rich in oligomers (left) or monomers
(right) separated by SEC of 7PA2 CM.
(B) A train of 300 single pulses at 1 Hz (5 min; small
gray bar) did not induce LTD in acute mouse hippo-
campal slices in the presence of CHO- CM (blue
squares, n = 6) but induced a significant LTD in
the presence of 7PA2 CM (red circles, n = 7).
(C–F) A standard LTD protocol of 900 single
pulses at 1 Hz (15 min; long gray bar) was applied
to slices treated with 7PA2 CM (C), synthetic
Ab1-42 (D), AD brain TBS extract (E), or SEC frac-
tions from 7PA2 CM (F). All are not significantly
different from their respective controls.
Insets in (B)–(F) represent typical field excitatory
postsynaptic potentials (fEPSPs) recorded before
(light) and 50 min after (dark) LFS. Horizontal cali-
bration bar, 10 ms; vertical bar, 0.5 mV.
RESULTS
Soluble Human Ab from Several
Sources Facilitates Hippocampal
LTD
Small, soluble Ab assemblies have been
obtained from a variety of sources,
including synthetic peptides, cell culture
medium, and human brain extracts
(Lambert et al., 1998; Podlisny et al., 1995;
McLean et al., 1999; Shankar et al., 2008).
A common feature among the soluble Ab
preparations used in the current study is
the presence of low-n assembly forms,
i.e., Ab oligomers that are slightly larger than the monomer but
much smaller than amyloid fibrils. When examined on denaturing
gels, these oligomers run principally as SDS-stable dimers and
trimers (Figure 1A). We recently reported that soluble oligomers
extracted directly from human (AD) cortex facilitate LTD induction
through activation of mGluR when a subthreshold (300 pulses,
1 Hz) stimulation is applied to hippocampal slices (Shankar
et al., 2008). To investigate the mechanisms underlying the
enhancement of LTD by soluble human Ab, we first used cell-
secreted Ab species obtained from a CHO cell line that stably
expresses hAPP with the V717F amyloidogenic AD mutation
(7PA2 cells). These cells release readily detectable levels of
monomeric and oligomeric Ab species into the medium in theNeuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc. 789
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Soluble Ab Enhances Long-Term Depressionabsence of insoluble aggregates (Podlisny et al., 1995; Walsh
et al., 2002). In accord with our recent work using soluble Ab
extracted from human cortex, we found that 7PA2 CM (but not
the CM of untransfected [CHO-] cells) facilitated the induction
of hippocampal LTD following a subthreshold, low-frequency
stimulus (LFS) (300 pulses at 1 Hz) that otherwise does not induce
LTD (79.7% ± 2.4%, n = 6, versus 93.4% ± 4.2%, n = 7, of base-
line fEPSP slope; p < 0.05) (Figure 1B). We next sought to estab-
lish the effects of soluble Ab on the expression of LTD using
a standard LTD-inducing protocol known to be NMDAR depen-
dent (Kemp and Bashir, 2001), namely, 900 pulses at 1 Hz. This
form of LTD was equally inducible in slices perfused with artificial
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Figure 2. Soluble Ab Enhances Hippo-
campal LTD through mGluR or NMDAR,
Depending on the Stimulation Protocol
(A) LTD induced by the 300-pulse protocol (gray
bar) in the presence of 7PA2 CM was blocked
upon coadministration of the nonselective group
I/II mGluR antagonist, MCPG (500 mM, red circles,
n = 6), but not the NMDAR antagonist, AP5 (50 mM,
black squares, n = 5). Horizontal colored bars
represent the corresponding means ± SEMs from
data shown in Figure 1B.
(B) LTD induced by the 900-pulse protocol (gray
bar) is independent of mGluR activation. Horizontal
colored bars represent the corresponding means ±
SEMs from data shown in Figure 1C.
(C) The 900-pulse LTD induced in slices in CHO-
CM was blocked by coadministering the NMDAR
antagonist, AP5 (50 mM, black squares, n = 8),
whereas LTD in slices in 7PA2 CM was unaltered
(red circles, n = 6). Horizontal colored bars from
data in Figure 1C.
(D) 900-pulse LTD in Ab monomer-treated slices
was blocked upon coperfusing AP5 (50 mM, black
squares, n = 5), whereas the LTD in oligomer-
treated slices was not (red circles, n = 6). Horizontal
colored bars represent the corresponding means ±
SEMs from Figure 1F.
(E) 7PA2 CM enhanced LTD was blocked by treat-
ment with D-AP5 at 100 mM (n = 5). Horizontal
colored bars represent the corresponding means ±
SEMs from Figure 2C.
(F) Dose-response curves of LTD blockade by AP5
in either CHO- CM (black squares) or 7PA2 CM
(red circles). Data are means ± SEMs.
Insets in (A)–(E) represent typical fEPSPs recorded
before (light) and 50 min after (dark) the LFS. Hori-
zontal calibration bar, 10 ms; vertical bar, 0.5 mV.
cerebrospinal fluid (ACSF) supplemented
with 7PA2 CM or CHO- CM (73.6% ±
2.6%, n = 9, versus 77.1% ± 2.1%, n = 9;
p > 0.05) (Figure 1C). Similar results were
observedusingsyntheticAb1-42 (Figure1D),
soluble extracts of human AD cortex con-
taining Ab oligomers (Figure 1E), or size-
exclusion chromatography (SEC) fractions
of 7PA2 CM enriched in either oligomers
or monomers (Figures 1A, right panel, and
Figure 1F). These data are consistent with
previous reports that synthetic Ab does not significantly change
the magnitude of NMDAR-dependent (i.e., 900-pulse) LTD
achieved in vitro (Raymond et al., 2003; Wang et al., 2002, 2004a).
To probe the mechanism of Ab-facilitated LTD, we used the
nonselective group I/II mGluR antagonist MCPG (500 mM) and
the NMDAR antagonist AP5 (50 mM). In agreement with our
previous finding using soluble Ab from AD cortex (Shankar
et al., 2008), the facilitation of 300-pulse LTD by 7PA2 CM was
dependent on activation of mGluR but not NMDAR, as the LTD
was MCPG sensitive and AP5 resistant (93.2% ± 6.1%, n = 6,
versus 80.4% ± 4.8%, n = 5; p < 0.05) (Figure 2A). Unlike the
300-pulse LTD, 900-pulse LTD induced in the presence of790 Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc.
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Soluble Ab Enhances Long-Term Depression7PA2 CM was not prevented by MCPG (78.5% ± 4.1%, n = 6,
versus 73.6% ± 2.6%, n = 9; p > 0.05) (Figure 2B). Interestingly,
50 mM AP5 fully blocked 900-pulse LTD in slices exposed to
CHO- CM but had no significant effect on the 900-pulse LTD in
slices exposed to the Ab-rich 7PA2 CM (100.6% ± 1.4%, n = 8,
versus 75.4% ± 3.4%, n = 6; p < 0.01) (Figure 2C). This AP5 resis-
tance noted with 7PA2 CM was also observed with soluble
synthetic Ab1-42 (see Figure S1A available online) and soluble
extracts of AD cortex containing Ab oligomers (Supp. Figure 1B;
data quantified in Supp. Figure 1C). Furthermore, application of
SEC fractions of 7PA2 CM revealed that the induction of AP5-
resistant 900-pulse LTD was specific to Ab oligomers, not mono-
mers (Figures 2D and S1C). These results using three distinct
sources of soluble low-n oligomers suggest that the LTD facili-
tated by Ab oligomers is mechanistically different from conven-
tional NMDAR-dependent LTD that is sensitive to 50 mM AP5.
Because the 900-LFS protocol for inducing LTD in the CA1 region
is well known to be NMDAR dependent (see Kemp and Bashir,
2001, and all control data in Figures 2C, 2D, and S1C), the resis-
tance to AP5 of the LTD induced in the presence of the various
soluble Ab preparations was unexpected. It has been reported
that synthetic Ab can increase NMDAR activity by acting as an
agonist or coagonist of NMDARs (Cowburn et al., 1997) and
increasing NMDA conductance (Wu et al., 1995). Consequently,
50 mM AP5 may not have been sufficient to completely block an
enhanced NMDAR activation mediated by Ab oligomers. When
we used a more potent isoform of AP5, D-AP5, and increased
the concentration to 100 mM, the soluble Ab-facilitated LTD was
now significantly prevented (96.5% ± 3.4%, n = 5) (Figure 2E).
Indeed, the block of Ab-facilitated LTD was dependent on AP5
dose (Figure 2F). Rescuing LTD expression in the presence of
7PA2 CM required much higher AP5 concentrations than those
needed to rescue LTD in the presence of CHO- CM (IC50: 17.4
versus 72.5 mM; p < 0.001), supporting the conclusion that active
NMDARs are involved in LTD facilitation by soluble Ab.
An Extracellular Glutamate Scavenger Restores Soluble
Ab-Enhanced LTD to Normal Levels
Because Aboligomers enhanced LTD through activation of gluta-
mate receptors, we asked whether this activity of soluble Abwas
dependent on extracellular glutamate concentration. To this end,
we used an enzymatic glutamate scavenger system (glutamic-
pyruvic transaminase [GPT] + pyruvate) to reduce extracellular
glutamate levels (Overstreet et al., 1997; Min et al., 1998). Expo-
sure of hippocampal slices to GPT alone (5 units/ml) had no effect
on baseline synaptic activity (data not shown). GPT + pyruvate
(2 mM) treatment 15 min prior to the application of CHO- CM or
7PA2 CM affected neither baseline activity nor the magnitude
of LTD induced by 900-LFS (CHO-: 82.6% ± 2.1%, n = 5; 7PA2:
81.8% ± 4.5%, n = 5) (Figure 3A); however, the LTD induced in
the presence of Ab and GPT could now be blocked by 50 mM
AP5 (95.1% ± 3.6%, n = 5) (Figure 3B). This result suggests that
elevated extracellular glutamate concentrations contribute to
the enhancement of LTD by soluble Ab. Similarly, treatment
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Figure 3. Selective Metabolism of Extracel-
lular Glutamate Prevents Soluble Ab-Facili-
tated LTD
(A) A glutamate scavenger system (glutamic pyr-
uvic transaminase [GPT, 5 unit/ml] + pyruvate
[2 mM]) has no significant effect on the fEPSP
baseline and 900-pulse LTD in CHO- or 7PA2 CM
treated slices. Horizontal colored bars represent
the corresponding means ± SEMs from Figure 1C.
Insets in (A)–(C) represent typical fEPSPs recorded
before (light) and 50 min after (dark) LFS; horizontal
calibration bar, 10 ms; vertical bar, 0.5 mV.
(B) 900-pulse LTD (gray bar) was blocked by AP5
(50 mM) in slices exposed to GPT + pyruvate for
15 min prior to 7PA2 CM (n = 6). Red horizontal
bar shows the LTD resistant to the same dose of
AP5 in the absence of exposure to scavengers.
(C) 300-pulse LTD (gray bar) was significantly pre-
vented by coadministering glutamate scavengers
with the 7PA2 CM. Horizontal colored bars repre-
sent the corresponding means ± SEMs from
Figure 1B.
(D) Paired-pulse facilitation in slices exposed to
7PA2 CM, CHO- CM, or 7PA2 CM + AP5 (50 mM)
measured before (white) or 30 min after (gray) add-
ing these media or else measured 50 min after
(black) a 900-pulse induction of LTD. At right are
typical traces of these field recordings from the
7PA2 group.
(E) Similar paired-pulse facilitation recorded by
whole-cell voltage clamping at 70 mV in CA1
pyramid cells before and 30 min after 7PA2 CM
exposure. At right are typical traces. Data are
means ± SEMs.Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc. 791
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LTD (94.4% ± 2.8%, n = 5) (Figure 3C). We conclude that the
enhancement of LTD by soluble Ab in both mGluR-dependent
and NMDAR-dependent conditions involves elevated extracel-
lular glutamate levels.
Paired-pulse facilitation (PPF) reveals whether alterations of
synaptic transmission are presynaptic. To assess whether
soluble Ab oligomers increase extracellular glutamate levels by
affecting presynaptic release probability, we measured PPF in
slicesexposed to CHO- CM, 7PA2 CM, or 7PA2 CM + AP5 (50mM)
at baseline, 30 min after these exposures, and then 50 min after
a 900-pulse LTD induction. PPF was not significantly different
between these three conditions (Figure 3D). To establish further
that soluble Ab does not alter presynaptic release, we performed
whole-cell recordings of pyramidal cells and found that PPF ratios
before and 30 min after 7PA2 CM exposure were not significantly
different (Figure 3E). The experiments described so far suggest
that the facilitation of LTD by soluble oligomeric Ab involves
elevated levels of extracellular glutamate, but not by altering
presynaptic release probability.
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Figure 4. Soluble Ab Oligomers Alter NMDAR-Medi-
ated EPSCs in Whole-Cell Voltage-Clamp Recordings
(A1) Isolated AMPA-EPSC and NMDA-EPSC were recorded
from 70 mV and +45 mV holding potentials, respectively,
plus pharmacological blockers. Black traces, CHO- CM
treated cells; gray traces, 7PA2 CM treated cells. (A2)
Summary data for CHO- CM (black) and 7PA2 CM (gray)
groups and for pretreatment with cyclothiazide (CTZ, 100 mM)
prior to 7PA2 CM (white). (A3) NMDA/AMPA EPSC ratios are
different in CHO- CM and 7PA2 CM.
(B1) Typical traces from CA1 pyramidal cells held at 70 mV
(black), isolated NMDA-EPSC in low Mg2+ with NBQX (10 mM)
and bicuculline (20 mM) at 70 mV (gray), and full blockage
of the NMDA current by AP5 (50 mM) (light gray). (B2)
Summary data for the isolated NMDA-EPSC before (pre)
and 20–30 min after 7PA2 CM exposure. Peak amplitudes
(gray) and total charge transfers (black) are expressed as
means ± SEMs.
(C1) The selective NR2B inhibitor, ifenprodil (3 mM), modestly
reduces NMDA charge transfers in control but markedly
reduces it in 7PA2 CM. (C2) 7PA2 CM significantly increases
the extrasynaptic response when synaptic NMDAR are first
blocked by MK-801.
(D) NMDA-mediated EPSC kinetic analysis: (D1) representa-
tive scaled traces before (black) versus after (gray) 7PA2 CM
exposure; (D2) summary data of rise time plotted versus
decay time before (pre) and after (post)7PA2 CM exposure.
Data are means ± SEMs.
The Ab-Mediated Increase in Synaptic
Glutamate Concentration Alters Properties
of Excitatory Transmission
We next sought to determine more precisely the
basis of soluble Ab-mediated alterations in glutama-
tergic transmission through whole-cell recordings.
AMPAR-mediated currents (AMPA-EPSC) and
NMDAR-mediated currents (NMDA-EPSC) were re-
corded from pyramidal neurons in slices treated
with CHO- CM or 7PA2 CM (Figure 4A1). Both
currents were significantly reduced by the soluble Ab-rich 7PA2
CM compared to the CHO- CM (AMPA 67% ± 4%, n = 18, p <
0.001; NMDA 79% ± 3%, n = 13, p < 0.01) (Figure 4A2). This result
was unexpected, as the increased extracellular glutamate
concentrations observed above should increase AMPA and/or
NMDA currents. However, the result could be explained if the
Ab-mediated rise in glutamate levels leads to receptor desensiti-
zation. To address this possibility, we applied a well-character-
ized inhibitor of AMPAR desensitization, cyclothiazide (CTZ,
100 mM), to the slices before exposure to 7PA2 CM; the AMPA
EPSC was no longer significantly decreased (CHO- CM: 115 ±
14 pA versus 7PA2 CM + CTZ: 96 ± 3 pA, n = 10; p > 0.05)
(Figure 4A2). Interestingly, we observed spiking activity escaping
voltage clamp in 6/10 cells recorded in the 7PA2 CM + CTZ condi-
tion (Figures S2A and S2B) but not in the CTZ-only condition
(three cells; data not shown), further suggesting alterations in
excitatory transmission due to supraphysiologic levels of extra-
cellular glutamate in the presence of soluble Ab. To assess
whether AMPAR desensitization is involved in the induction of
LTD by soluble Ab, CTZ was applied to brain slices, and 900-pulse792 Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc.
Neuron
Soluble Ab Enhances Long-Term DepressionLTD was induced; the LTDs were not significantly different in
CHO- versus 7PA2 CM (Figure S2C), suggesting that AMPAR
desensitization is not required for the LTD induction.
To preserve the neuronal glutamate uptake expected under
normal physiological function, we repeated the single-cell record-
ings at 70 mV rather than at positive potentials (Grewer and
Rauen, 2005). NMDA-EPSC was isolated in low Mg2+ (0.1 mM)
and with pharmacological blockade of AMPAR (with NBQX,
10 mM) and GABA-R (with BIC, 20 mM) (Figure 4B1). Under these
conditions, the NMDAR-EPSC was again found to be decreased
by 7PA2 CM (78% ± 3%, n = 10; p < 0.01) (Figure 4B2). The
NMDA-EPSC reduction could be due to NMDAR desensitization
in the presence of increased extracellular glutamate levels (Sar-
antis et al., 1993). To better understand the NMDA current
changes, we quantified charge transfers, calculated as the area
under the curve of the NMDA-EPSC. In contrast to the reduction
in peak amplitude, the total charge transfer was not decreased by
the Ab-rich 7PA2 CM (96% ± 2% of pretreatment values, n = 11;
p > 0.05) (Figure 4B2). Because NR2B receptors have a 2- to
3-fold higher sensitivity for glutamate than do NR2A receptors
(Kutsuwada et al., 1992), we asked whether NR2B receptors
played the principal role in the Ab-mediated effect on NMDA
currents. The selective NR2B receptor inhibitor, ifenprodil (3 mM),
modestly inhibited the NMDA-EPSC total charge transfer under
control (CHO- CM) conditions (81% ± 2%, n = 8) (Figure 4C1).
However, ifenprodil strongly and significantly inhibited the
NMDA-EPSC charge transfer in the presence of 7PA2 CM (55% ±
2%, n = 9; p < 0.05) (Figure 4C1), suggesting enhanced activation
of NR2B-subunit-containing NMDA receptors. The NR2B subunit
is considered to be predominantly present in extrasynaptic
NMDA receptors (Tovar and Westbrook, 1999). We selectively
blocked synaptic NMDAR with MK-801, an irreversible, use-
dependent NMDA channel blocker, washed it out, and perfused
with7PA2 CM under the aboveNMDA-EPSC isolating conditions.
The NMDA-EPSCs were markedly increased (202% ± 10% of the
CHO- CM level, n = 5; p < 0.01) (Figure 4C2). Taken together, the
above results suggest that soluble Ab oligomers increase NR2B-
mediated NMDAR activity and enhance extrasynaptic responses.
Spillover of increased extracellular glutamate remained as the
most parsimonious explanation for the relative increases in
NMDA currents, activation of NR2B receptors, and extrasynaptic
responses in the presence of Ab oligomers. To further support
this interpretation, we analyzed the NMDA EPSC kinetics, i.e.,
the 10%–90% rise time and the decay time constant. While the
peak amplitude decreased slightly after 7PA2 CM treatment,
the rise time (16 ms versus 20 ms for pre- versus postexposure;
p < 0.05) and decay time (100 ms versus 109 ms for pre- versus
postexposure; p < 0.05) were significantly prolonged (Figure 4D),
suggesting increased diffusion distance and dwelling times, i.e.,
that neurotransmitter spillover is enhanced upon exposure to
soluble Ab oligomers.
Soluble Ab Enhances LTD through Inhibition
of Glutamate Uptake
Our findings above that soluble Ab-enhanced LTD may activate
a larger population of NMDARs can be considered in terms of
Ab interrupting glutamate reuptake (Harkany et al., 2000; Gu
et al., 2004). To investigate this possibility, we examined theeffects of a well-characterized glutamate uptake inhibitor,
TBOA. Soluble Ab extracted from AD brain or present in 7PA2
CM (Figure 1B) facilitates LTD in CA1 after a 300-LFS protocol,
whereas this low stimulus induces weak or no LTD in control-
treated slices. To test whether inhibiting glutamate uptake itself
facilitates LTD, the 300-LFS protocol was applied after a 30 min
TBOA treatment (15mM). Closely similar to our results with soluble
Ab treatment in this 300-LFS mode (Figure 1B), we found that
TBOA alone induced LTD in an NMDAR-independent but
mGluR-dependent manner (TBOA alone: 74% ± 4.5%, n = 5;
TBOA + AP5: 78.1% ± 3.5%, n = 5; TBOA + MCPG: 91% ±
4.6%, n = 6) (Figure 5A). Similar to the 900-pulse LTD induced in
the presence of soluble Ab (Figure 2), the 900-pulse LTD induced
in the presence of TBOA was also resistant to 50 mM AP5 but was
prevented by 100mM D-AP5 (TBOA: 73.5% ± 3.4%, n = 5; TBOA +
AP5: 76.9% ± 5.6%, n = 5; TBOA + D-AP5: 94.2% ± 2.8%, n = 5;
p < 0.01 compared to TBOA + AP5) (Figure 5B).
To assess whether TBOA-enhanced LTD has mechanistic
similarity with soluble Ab, we recorded the TBOA-induced LTD
in a repetitive 900-LFS paradigm to saturate the LTD response,
then washed out the TBOA and replaced it with 7PA2 CM
(Figure 5C). When 900-LFS was then performed, there was no
further increase in LTD (96.1% ± 9.1% of renormalized baseline
measured 40 min after LFS, n = 5; p > 0.05) (Figures 5C and 5D).
This occlusion experiment suggests that these two forms of LTD
share similar mechanisms. Interestingly, if we first applied 7PA2
CM and saturated the LTD, then the usual dose (15 mM) of TBOA
significantly reduced baseline neurotransmission (to 78% of the
renormalized baseline at 30 min) (Figure S3A), and this effect was
similar to that of a higher dose of TBOA alone (50 mM) on the
baseline (81% at 30 min) (Figure S3B). The latter results further
substantiate a shared mechanism between TBOA and soluble
Ab on perturbation of neurotransmission. We also examined
DHK (500 mM), an inhibitor of glial glutamate transporter (GLT-1),
but the 900-pulse LTD observed in the presence of this agent
was largely prevented by the standard 50 mM AP5 dose
(89.2% ± 3.2%, n = 6, versus 77.5% ± 2.9%, n = 6, p < 0.05,
Figure S3C), suggesting specificity for neuronal, not glial, gluta-
mate transporters in the enhancement of the 900-pulse LTD.
The effects of soluble Ab in inhibiting HFS-induced LTP have
been well established using several types of Ab preparations,
and we confirmed this here using soluble Ab-rich 7PA2 CM
(CHO- CM: 144.7% ± 5.4%, n = 7, versus 7PA2 CM: 108.1% ±
6.6%, n = 7; p < 0.001) (Figure 5E). TBOA similarly inhibited
HFS-induced LTP (vehicle: 151.3% ± 4.8%, n = 6, versus
TBOA: 112.2% ± 3.1%, n = 6; p < 0.001) (Figure 5F). These results
support our conclusion that the effects of soluble Ab on synaptic
plasticity mimic those observed with the blockade of neuronal
glutamate uptake.
To assess directly whether soluble Ab inhibits glutamate
uptake as all of the above data suggest, we measured the uptake
of radiolabeled glutamate by isolated synaptosomes (see Exper-
imental Procedures). As a positive control, TBOA decreased
glutamate uptake in the synaptosomal preparation in a dose-
dependent manner (IC50 = 73.9 mM) (Figure 5G). Synthetic Ab1-42
significantly decreased glutamate uptake into synaptosomes
(69% ± 6% of vehicle treatment, n = 15; p < 0.01), similar to the
effects of TBOA (41% ± 4% at 50 mM, n = 5; p < 0.01)Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc. 793
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Soluble Ab Enhances Long-Term Depression(Figure 5H). This biochemical evidence further supports our
hypothesis that soluble Ab impairs neuronal glutamate uptake
and can thereby increase extracellular glutamate concentration
and subsequent NMDAR activation.
Extracellular Calcium Influx, Not Intracellular Stores,
Contributes to Soluble Ab-Facilitated LTD
To assess whether alterations in calcium influx through NMDARs
mediate the facilitation of LTD by soluble Ab, the ACSF calcium
concentration was reduced to 0.5 mM prior to the application of
soluble Ab and 900-LFS to the brain slices. This reduction of
extracellular calcium concentration prevented LTD induction in
A B
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Figure 5. Soluble Ab-Enhanced LTD In-
volves Impaired Glutamate Reuptake
(A) LTD was induced by 300 pulses (gray bar) when
just the glutamate uptake inhibitor, TBOA (15 mM),
was perfused (black squares, n = 5). This TBOA-
mediated LTD was prevented by mGluR antago-
nist MCPG (500 mM, blue triangles, n = 6) but
not by NMDAR antagonist AP5 (50 mM, red circles,
n = 6).
Insets in (A)–(F) represent fEPSPs recorded before
(light) and 50 min after (dark) either LFS (in A–C)
or HFS (in E and F). Horizontal calibration bars,
10 ms; vertical bars, 0.5 mV.
(B) A 900-pulse LTD facilitated by TBOA was resis-
tant to a standard dose of AP5 (50 mM, red circles,
n = 6), but it could be blocked by D-AP5 (100 mM,
blue triangles, n = 6).
(C) Saturation of 900-pulse LTD occurring in the
presence of TBOA (black horizontal bar) occludes
further LTD in the presence of 7PA2 CM (red hori-
zontal bar).
(D) Summary data from occlusion experiments as
in (C): left bar, evoked fEPSP was renormalized
to baseline values (i.e., point 3 in C) before addition
of 7PA2 CM to the perfusate and an additional LFS
(right bar).
(E) LTP induced by high-frequency stimulation
(HFS) was prevented in slices in 7PA2 CM (red
circles) but unaffected in slices in CHO- CM (black
squares).
(F) HFS-induced LTP was similarly prevented by
TBOA.
(G) Dose-dependent inhibition of glutamate up-
take by TBOA in hippocampal synaptosomes.
(H) Pretreatment with soluble synthetic Ab1-42
impaired glutamate uptake in hippocampal synap-
tosomes in a fashion similar to TBOA treatment at
50 mM. Data are means ± SEMs as percentage of
vehicle alone; **p < 0.01.
the presence of either 7PA2 or CHO- CM
(Figure 6A). To test whether extracellular
calcium is required for the NMDAR-medi-
ated enhancement of LTD by soluble Ab,
we applied 50 mM AP5 and varied the
extracellular Ca2+ concentration between
0.5 mM and 6 mM (Figure 6A). The LTD
induced by 900-LFS in the presence of
AP5 + CHO- CM was fully blocked when
the Ca2+ concentration was 1 mM or 2.5 mM, and only a small
AP5-resistant LTD (86.4% ± 4.5%, n = 6) occurred at the highest
Ca2+ concentration (6 mM). In contrast, LTD induced in presence
of 7PA2 CM was significantly prevented by 50 mM AP5 at low
(1 mM) Ca2+ concentration (7PA2 CM: 80% ± 4.2%, n = 5, versus
7PA2 CM + AP5: 93.2% ± 3.4%, n = 6; p < 0.05) but not at normal
(2.5 mM: 75.4% ± 3.4%, n = 6) or high (6 mM: 70.4% ± 3.4%, n = 5)
Ca2+ concentrations. These results indicate that Ab-enhanced
LTD is dependent on extracellular calcium concentration.
To assess whether intracellular calcium stores also regulate
Ab-mediated LTD, as they have been reported to do for Abneuro-
toxicity (Demuro et al., 2005), we tested two compounds that794 Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc.
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U73122. Although ryanodine (20 mM) and U73122 (10 mM) each
prevented 900-LFS LTD induction in slices treated with CHO-
CM, they did not alter the LTD facilitation by 7PA2 CM (87% ±
2.7%, n = 5, versus 76% ± 3.2%, n = 5, for ryanodine, p < 0.05)
(Figure 6B) (96.2% ± 3.4%, n = 4, versus 74.6% ± 4.6%, n = 6,
for U73122, p < 0.01) (Figure 6C). This suggests that soluble
Ab-facilitated LTD requires extracellular calcium influx but not
intracellular calcium release.
Activation of Calcineurin and GSK-3, but Not p38MAPK,
Is Required for Ab-Mediated LTD
When cytosolic calcium reaches critical concentrations, certain
LTD-related signaling pathways are activated (Kemp and Bashir,
2001). For example, NMDAR-dependent LTD in the CA1 region
recruits calcineurin (PP2B) and p38 MAPK cascades (Mulkey
et al., 1994; Bolshakov et al., 2000; Li et al., 2006). We examined
these two signaling pathways using their respective inhibitors,
FK506 (20 mM) and SB203580 (5 mM). Whereas blocking p38
MAPK activation with SB203580 prevented conventional 900-
pulse LTD induction (i.e., in CHO- CM), it did not significantly
affect the LTD induced in the presence of soluble Ab-rich 7PA2
CM (94.6% ± 2.5%, n = 7, versus 73.9% ± 4%, n = 6; p < 0.01)
(Figure 6D). In contrast, PP2B function was required for LTD
induced both in the absence and presence of soluble Ab
(Figure 6E). Glycogen synthase kinase-3 (GSK3)-mediated
signaling was recently reported to play an important role in
LFS-induced LTD (Peineau et al., 2007), and it has also been
implicated in Ab-mediated neurotoxicity in cultured hippocampal
slices (Nassif et al., 2007). Accordingly, we treated slices with the
GSK-3b inhibitor, SB415286 (10 mM), for 30 min prior to applying
either CHO- CM or 7PA2 CM and then performed 900-LFS. LTD
could not be induced in either condition (94.3% ± 4.7%, n = 6,
versus 98.4% ± 2.6%, n = 6) (Figure 6F), suggesting that GSK-3b
activity is required for both conventional and soluble Ab-medi-
ated LTD. To further verify that glutamate uptake inhibition shares
similar mechanisms with soluble Ab as regards LTD induction,
ryanodine, SB203580, and FK506 were each applied to the slices
prior to treatment with TBOA. Entirely consistent with the results
for Ab-mediated LTD, both intracellular Ca2+ release and p38
MAPK activation were not required for the TBOA-mediated LTD,
whereas PP2B activity was (Figures 6G–6I).
To provide further information about the receptor mechanisms
of LTD facilitation by soluble Ab, we took advantage of Ras-
guanine nucleotide-releasing factor 1 (Ras-GRF1) knockout
mice, which are deficient in the ability to mount an LTD response
(Li et al., 2006). Ras-GRF proteins are best known for their ability
to activate Ras/Erk through their CDC25-GEF domains and acti-
vate the Rac/p38 cascade through their DH-GEF domains, which
act as calcium sensors for different classes of NMDARs and
drive the activation of distinct MAP kinase family members. As
expected, hippocampal slices from these Ras-GRF1/ mice
did not express LTD when 900-LFS was administered in the
presence of CHO- CM. In contrast, LTD was elicited in the pres-
ence of the oligomer-rich 7PA2 CM (99.4% ± 2.9%, n = 6, versus
75.1% ± 2.9%, n = 7; p < 0.01) (Figure S4A). This soluble Ab-facil-
itated LTD in the Ras-GRF1/ mice was not blocked by 500 mM
MCPG (Figure S4B) nor by 50 mM AP5 (Figure S4C), but it wassignificantly decreased by 100 mM AP5 (91.6% ± 3.1%, n = 5,
p < 0.05) (Figure S4C). Furthermore, the p38 MAPK inhibitor
(SB203508) had no effect on the Ab-facilitated LTD (80.2% ±
4.8%, n = 5) (data not shown), whereas pretreatment with either
the calcineurin inhibitor (FK506) or the GSK-3b inhibitor
(SB415286) significantly prevented the LTD associated with
7PA2 CM (95.6% ± 4.8%, n = 6, and 88.4% ± 4.7%, n = 6, respec-
tively) (Figure S4D). Therefore, soluble Ab bypassed the nonfunc-
tional LTD induction pathway in Ras-GRF1/ mice, a pathway
that is normally sensitive to 50 mM AP5 in wild-type mice.
DISCUSSION
Given the mounting evidence that soluble Ab oligomers mediate
synaptic impairment in AD, elucidating the precise molecular
pathways by which this occurs has important implications for
treating and preventing the disease. Here, we demonstrate
that soluble Ab oligomers facilitate LTD in the hippocampus
through a mechanism that appears to involve the inhibition of
glutamate uptake. With a weak (300-pulse) LFS, Ab-mediated
LTD was prevented by MCPG but not AP5, and with a conven-
tional (900-pulse) LFS, the LTD was prevented only by a high
(100 mM), not a standard (50 mM), dose of AP5. Extracellular
glutamate scavengers effectively prevented Ab-enhanced LTD.
Mechanistically, soluble Ab oligomers caused glutamate spill-
over, and their ability to facilitate LTD required an influx of extra-
cellular calcium but did not detectably require Ca2+ release from
intracellular stores. Once Ca2+ enters the neuron, it is known to
trigger PP2B and GSK3 signaling pathways, and we implicated
these in the Ab-facilitated LTD induction.
Importantly, Ab facilitation of LTD was closely mimicked by
pharmacologically inhibiting neuronal (but not glial) glutamate
uptake, consistent with the rescue of Ab-LTD by the glutamate
scavenger. In accord, we found that Ab significantly impaired
glutamate uptake by synaptosomes, suggesting that Ab facili-
tates LTD in part by altering synaptic glutamate recycling. These
results support the hypothesis that excess synaptic glutamate
caused by Ab mechanistically alters LTD induction in hippo-
campus. It should be emphasized that the effects of soluble Ab
we describe in this study are attributable to soluble oligomers
(Figure 1A), as no larger assemblies (protofibrils, fibrils) were
present, and SEC-isolated oligomers but not monomers
conferred the effects on LTD (Figure 2D). A summary mechanism
incorporating all of our findings is proposed in Figure 7.
We focused on the NMDAR-dependent induction of LTD, a
widely used protocol for LTD studies. There have been contradic-
tory findings among the few studies of the effects of Ab on LTD
(Kim et al., 2001; Wang et al., 2002; Raymond et al., 2003; Wang
et al., 2004a). Hsieh et al. (2006) showed that Ab secreted by
neurons in hippocampal slices transfected with mutant human
APP could induce LTD via an mGluR-dependent mechanism
involving AMPAR internalization. Moreover, Chang et al. (2006)
reported that aged APP/Presenilin-1 double knockin mice having
reduced AMPAR mEPSCs were resistant to LTD induction, sug-
gesting a floor effect for synapse depression following prolonged
exposure to Ab. Our new data indicate that soluble Ab oligomers
can induce hippocampal LTD, although the mechanisms do not
follow canonical p38 MAPK pathways.Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc. 795
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Figure 6. LTD Facilitated by Soluble Ab or TBOA Share Similar Signaling Pathways
(A) Conventional LTD (in CHO- CM, black squares) and Ab-enhanced LTD (in 7PA2 CM, red circles) induced by the 900-pulse LFS in the presence of AP5 (50 mM)
were plotted as a function of increasing extracellular calcium concentrations in the perfusate. Light blue area represents the LTD obtained in the CHO- CM alone
(without AP5). Data are means ± SEMs.
(B) Ryanodine (20 mM) given 30 min prior to 900 pulses partially blocked the LTD in CHO CM (black squares, n = 5) but produced no block of the 7PA2-facilitated
LTD (red circles, n = 6).
(C) U73122 (10 mM) (applied 45 min prior to 900 pulses) fully blocked LTD in the presence of CHO- CM (black squares, n = 6) but had no effect in the presence of
7PA2 CM (red circles, n = 6).
(D) 900-pulse LTD was blocked by p38 MAPK inhibitor, SB203580 (5 mM), in CHO- CM (black squares, n = 7) but not in 7PA2 CM (red circles, n = 7).
(E) Calcineurin inhibitor, FK-506 (20 mM) perfused 40 min prior to 900 pulses prevented LTD in both CHO- CM (black squares, n = 5) and 7PA2 CM (red circles,
n = 6).
(F) GSK-3b inhibitor, SB415286 (10mM) perfused 60 min prior to 900 pulses prevented LTD in both CHO- CM (black squares, n = 6) and 7PA2 CM (red circles, n = 7).
(G) LTD enhanced by TBOA (15 mM) was likewise resistant to ryanodine (n = 5).796 Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc.
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Soluble Ab Enhances Long-Term DepressionFigure 7. Schematic of the Principal Pathways Implicated by This Study in Conventional LTD and in LTD Facilitated by Soluble AbOligomers
(Left panel) Conventional LTD requires NMDAR-mediated influx of extracellular calcium and liberation of intracellular calcium stores. This ultimately activates
PP2B, GSK-3b, or p38 MAPK signaling pathways that induce LTD. (Right panel) Soluble Ab oligomers lead to activation of more NMDAR, leading to extracellular
calcium influx and activation of PP2B and GSK-3b pathways to facilitate LTD. Our data suggest that Ab oligomers decrease glutamate uptake by neuronal trans-
porters (red x’s), resulting in the enhanced activation of NMDARs and thus facilitation of LTD-inducing pathways.Synthetic Ab has been shown to increase NMDAR-mediated
currents in rat dentate gyrus (Wu et al., 1995) or enhance
NMDA response in the hippocampus after a 15 min exposure
in vivo (Molna´r et al., 2004). Our current results show that soluble
Ab oligomers depressed AMPAR currents (Figures 4A and 4B),
but this was likely due to desensitization. Earlier work has sug-
gested that NR2B-containing NMDARs play a major role in
normal LTD induction (Liu et al., 2004), although some recent
evidence is not in agreement (Morishita et al., 2007). Our study
suggests that soluble Ab oligomers can significantly increase
NR2B receptor activation, as demonstrated by an increased
ifenprodil-sensitive component of the NMDAR-EPSC following
exposure to soluble Ab. NR2B receptors are specifically coupled
to SynGAP (Kim et al., 2005), and their activation would thus
inhibit the Ras-Erk signaling pathway known to be required for
LTP, instead favoring LTD induction. Although some studies
have colocalized Ab with NMDAR at synapses (Dewachter
et al., 2009; Lacor et al., 2007), it remains unclear whether these
are a direct target of the peptide, and other studies have sug-
gested Ab interactions with voltage-dependent calcium chan-
nels (VDCCs) (Ueda et al., 1997), mGluRs (Wang et al., 2004b),nicotinic receptors (Dineley et al., 2001; Snyder et al., 2005), or
insulin receptors (Townsend et al., 2007), all of which could
modulate NMDAR activity. It remains plausible that the hydro-
phobic Ab oligomers actually interact with lipid and/or protein
targets upstream of these various receptors, perturbing their
function secondarily.
Extrasynaptic glutamate spillover is a phenomenon that has
been implicated in cross-talk among hippocampal synapses
(Asztely et al., 1997; Min et al., 1998; Scimemi et al., 2004). Inhibi-
tion of glutamate uptake at the synapse (e.g., by soluble Ab) can
significantly increase the extracellular glutamate concentration
and thereby enhance glutamate spillover toneighboring synapses.
Electrophysiologically, NMDA currents will be increased and
their rise and decay time courses significantly prolonged, due to
the increased distance between the glutamate release site and
the target receptors. In addition, extrasynaptic NMDAR activity
will be increased bysynapticglutamate accumulation. Our present
results do not fully meet these criteria, as we found that soluble Ab
depressed peak NMDAR currents. We hypothesize that Ab oligo-
mers depress NMDA currents as a result of desensitization of the
receptors. It is of related interest that several glutamate uptake(H) TBOA-enhanced LTD was prevented by the calcineurin inhibitor (FK 506, black circles, n = 5) but not by the p38 MAPK inhibitor (SB203580, red diamonds,
n = 5).
(I) Summary data for actions of the signaling pathway modulators on Ab- and TBOA-enhanced LTD. The horizontal gray bar represents mean LTD in TBOA alone
(Figure 5B), and the horizontal light orange bar represents mean LTD in 7PA2 CM alone (Figure 1C). Data are means ± SEMs.Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc. 797
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et al., 1993; Maki et al., 1994; Asztely et al., 1997), as we show
for soluble Ab oligomers here. Thus, Ab-mediated decreases in
glutamate uptake and consequent accumulation of extracellular
glutamate could induce NMDAR desensitization and/or activation
of presynaptic mGluRs, thereby reducing the peak amplitudes of
the NMDA currents.
Glutamate excitotoxicity has been hypothesized to have a role
in AD pathogenesis. Dysfunction of glutamate transporters has
been implicated in this pathway (Masliah et al., 1996; Jacob
et al., 2007). Synthetic Ab has been shown to inhibit glutamate
uptake in cultured astrocytes (Harris et al., 1996; Harkany
et al., 2000; but see Ikegaya et al., 2002) and oocytes (Gu
et al., 2004). Extracellular glutamate concentration is tightly
controlled in the brain by a family of membrane transporters,
predominantly expressed by perisynaptic astrocytes (Danbolt,
2001). Their role is to regulate the glutamate released at
synapses and to prevent spillover of the transmitter to extrasy-
naptic receptors. Our results showing that soluble Ab facilitates
LTD through both mGluR (300-LFS protocol) and NMDAR (900-
LFS protocol) pathways is supported by our concomitant finding
that a common upstream element, the glutamate transporter, is
also regulated by soluble Ab. In vivo microdialysis recently re-
vealed that microinjection of the soluble Ab-rich 7PA2 CM can
significantly increase the interstitial fluid levels of glutamate—
but not GABA or aspartate—in hippocampus (O’Shea et al.,
2008). Inhibition of glutamate uptake by TBOA has been shown
to increase spontaneous epileptiform discharges, and this
increased excitability can be blocked by AP5 (Campbell and Ha-
blitz, 2004). Interestingly, Ab has also been found to significantly
increase spontaneous nonconvulsive seizure activity in cortical
and hippocampal networks in APP-transgenic mice (Palop
et al., 2007). The precise mechanism by which soluble Ab oligo-
mers interfere with glutamate transporters at the synapse
remains to be determined. Given the numerous distinct recep-
tors and channel proteins reported to be altered by Ab to date,
we speculate that the hydrophobic Ab oligomers bind principally
to membrane lipids and thereby secondarily interrupt the struc-
ture and function of synaptic transmembrane transporters and
channels, leading to changes in the transduction of intracellular
signaling cascades. Such a mechanism would be consistent
with the direct effect of soluble Ab on glutamate uptake by iso-
lated synaptosomes in vitro (Figure 5H).
Calcium is a second messenger that controls many cellular
processes, including neuronal excitability, synaptic plasticity,
and neuronal death. The increase in postsynaptic calcium that
results in LTD can arise from a number of sources. For example,
extracellular Ca2+ influx can occur through NMDARs or VDCCs
(Kemp and Bashir, 2001), and intracellular Ca2+ release can
stem from activation of the ryanodine receptor (RyR) and the
inositol 1,4,5-trisphosphate receptor (IP3R). Our data (Figures
6A–6C) show that conventional hippocampal LTD requires
extracellular Ca2+ influx through NMDARs and recruits intracel-
lular stores from IP3R and possibly RyR, in line with previous
studies on hippocampal LTD (Kemp and Bashir, 2001).
However, among these possible calcium sources, Ab-facilitated
LTD only required NMDAR activation and enhanced extracellular
calcium entry. An increase in cytosolic calcium can trigger798 Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc.signaling cascades involved in LTD induction, including PP2B,
p38 MAPK, and GSK3 (Mulkey et al., 1994; Bolshakov et al.,
2000; Li et al., 2006; Peineau et al., 2007). The differences
between our study and previous reports implicating Ab in the
activation of p38 MAPK (Hsieh et al., 2006; Origlia et al., 2008)
could lie in the experimental conditions, for example, acute sli-
ces versus dissociated neuronal cultures or field versus whole-
cell recordings.
In conclusion, the findings described here suggest that soluble
Ab oligomers facilitate LTD through both NMDARs and mGluRs
by interfering with glutamate recycling at the synapse (Figure 7).
Our study also suggests that additional mechanisms may
underlie LTD in AD pathological states beyond those described
previously through the NMDAR-p38/MAPK pathway. The recep-
tors and signaling molecules activated by Ab as described in
this study could represent additional therapeutic targets in
Alzheimer’s disease.
EXPERIMENTAL PROCEDURES
Ab Preparations
Secreted human Ab peptides were collected and prepared from the condi-
tioned medium (CM) of a CHO cell line (7PA2) that stably expresses human
APP751 containing the V717F AD mutation (Podlisny et al., 1995). Cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal
bovine serum, 1% penicillin/streptomycin, 2 mM L-glutamine, and 200 mg/
ml G418 for selection. Upon reaching 95% confluency, the cells were
washed and cultured overnight (15 hr) in serum-free medium. CM was
collected, spun at 1500 3 g to remove dead cells and debris, and stored at
4C. The CM was concentrated 10-fold with a YM-3 Centricon filter (Walsh
et al., 2005). Aliquots of concentrated 7PA2 CM were stored at 80C.
Synthetic Ab1-42 (Biopolymer Lab., Dept. of Neurology, UCLA) was dissolved
in water and incubated at 37C for 10 days, then aliquoted (50 ml) and stored
at 80C.
Hippocampal Slice Electrophysiology
The procedures for the hippocampal slice preparation and field excitatory
postsynaptic potentials (fEPSPs) recordings in the CA1 region of mouse hippo-
campus were described previously (Li et al., 2006; Shankar et al., 2008). A
bipolar stimulating electrode (FHC Inc., Bowdoin, ME) was placed in the
Schaffer collaterals to deliver test and conditioning stimuli. A borosilicate glass
recording electrode filled with artificial cerebrospinal fluid was positioned in
stratum radiatum of CA1. Test responses were recorded for 30–60 min prior
to beginning the experiment to ensure stable responses. The field potentials
were amplified 1003 using an Axon Instruments 200B amplifier and digitized
with Digidata 1322A. Traces were obtained by pClamp 9.2 and analyzed using
the Clampfit 9.2 program. To induce LTD, either 300 or 900 pulses at low
frequency (1 Hz) stimulation (LFS) were applied to the slices. LTP was induced
by two sequential high-frequency stimulations (HFS: 100 Hz for 1 s, then
repeated after 20 s). All LTD/LTP values represent fEPSP slopes measured
50 min after the conditioning stimulus unless stated otherwise. Two-tailed
Student’s t test and one-way analysis of variance (ANOVA) were used to deter-
mine statistical significance.
Whole-cell recordings were made from the soma of visually identified pyra-
midal neurons located in CA1 of the hippocampus. Patch pipettes (57 MU)
were filled with an internal solution containing (in mM) 110 Cs-gluconate,
20 CsCl, 10 HEPES, 4 NaCl, 0.5 EGTA, 2 MgCl2, 2 Na2ATP, and 0.25 NaGTP,
titrated with CsOH to pH 7.4. The excitatory postsynaptic currents (EPSCs)
were recorded following stimulation of Schaffer collaterals 150 mm from the
CA1 cell body with a bipolar electrode. AMPA-mediated EPSCs were recorded
at a holding potential of70 mV in the presence of 10 mM bicuculline (BIC) and
50 mM AP5. NMDA-mediated EPSCs were recorded at +45 mV in ACSF con-
taining 20 mM BIC and 10 mM NBQX, or else at 70 mV in 0.1 mM Mg2+
ACSF containing BIC and NBQX. Series resistance was kept 1530 MU and
Neuron
Soluble Ab Enhances Long-Term Depressionmonitored throughout each recording. Cells were excluded from data analysis
if the series resistance changed by >20% during the course of the experiment.
All patch-clamp experiments were performed at 24C.
Glutamate Uptake Assay
Preparation of crude synaptosomal fractions and glutamate uptake assay
were performed as described by Yang et al. (2005) with minor modifications.
Briefly, hippocampal slices were treated for 2 hr with soluble Ab, TBOA, or
DMSO, then homogenized in 0.32 M sucrose, 1 mM EDTA, 4 mM Tris, and
10 mM glucose (pH 7.4) on ice. Homogenates were centrifuged at 1000 3 g
for 10 min, and subsequent supernatants were spun at 9000 3 g for 10 min.
Final pellets were resuspended in HEPES buffer solution to yield a protein
concentration of 0.25 mg/ml. To avoid treatment washout, crude synapto-
somes were treated with the same respective agents for 45 min at 37C.
Then, they were incubated with 10 nM [3H]glutamate (20–60 Ci/mmol; Perkin
Elmer, Boston, MA) and 30 mM unlabeled glutamate for 5 min. The uptake
was stopped by placing the samples on ice and spinning at 15,000 rpm for
10 min at 4C. Pellets were washed and resuspended in ice-cold PBS. Gluta-
mate uptake was counted on an LS6500 multipurpose scintillation counter.
The absolute number of counts taken up varied from 500 to 40,000 counts
per minute (cpm), with a background of 20 cpm.
Drug Treatments
Paired control and experimental hippocampal slices from a single mouse were
maintained together in a single chamber, except during individual drug treat-
ments. The following antagonists were purchased from Tocris (Ellisville,
MO): DL-2-amino-5-phosphonopentanoic acid (AP5), MK-801, MCPG, cyclo-
thiazide, NBQX, (-)-bicuculline methiodide, SB203580, SB415286, Ryanodine,
U73122, DL-threo-b-benzyloxyaspartic acid (TBOA) and dihydrokainic acid
(DHK). Glutamic-pyruvic transaminase, pyruvic acid, Ifenprodil, and FK506
were purchased from Sigma (St Louis, MO).
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Supplemental Data include four figures and their legends and can be found
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